News|Slideshows|July 31, 2024

Women's Health: Best and Worst States Ranked on 32 Measures of Access, Quality, Outcomes

Maternal mortality nearly doubled between 2018 and 2022 in the US. The Commonwealth Fund ranks states on how well they care for women.

Life expectancy for women in the US is the lowest recorded since 2006, according to data collected and analyzed by the Commonwealth Fund for its 2024 State Scorecard on Women’s Health and Reproductive Care. The scorecard measured performance across 3 areas critical for understanding the overall ability of individual states to promote women's health overall and their ability for bearing children: health outcomes; health care quality and prevention; and coverage, access, and affordability. The slides above summarize the scorecard findings across the 3 main areas of focus.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Related to this article

October 6th, 2026

9 Drugs Approved for Primary Care: Q3 2026

Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

October 29th, 2026

Night Sweats in Midlife Women: A Q&A With Cheryl Cox Kinney, MD

Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.

October 29th, 2026

Menopause Care in Primary Care: Closing Diagnosis and Treatment Gaps

TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.

October 28th, 2026

CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026

Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.

October 26th, 2026

Elinzanetant Reduced Menopausal VMS Frequency by ≥50% in 67% of Women at Week 12: TMS 2026

TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.

October 26th, 2026

Nearly 80% of Women May Not Initiate Menopause Hormone Therapy: A Q&A With Intira Sriprasert, MD, PhD

TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.

October 23rd, 2026

Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds

TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.

October 23rd, 2026

JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS

JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.

Women's Health: Best and Worst States Ranked on 32 Measures of Access, Quality, Outcomes

Related to this article

Trending on Patient Care Online

Mediterranean Diet Linked to Lower Odds of Adult Acne in New Study

4 FDA Decisions for Primary Care to Know from October 2026

Why a Negative Endometrial Biopsy May Not End the Abnormal Bleeding Workup

Abbott's Amulet 360 Linked to Low Stroke Risk at 1 Year in Late-Breaking Research

FDA Clears 15-Minute Blood Test to Help Distinguish Bacterial From Viral Infections